Smith & Nephew SNATS (NYSE:SNN) Cut to “Strong Sell” at Zacks Research

Posted by Geri Gentry on Nov 7th, 2026

Smith & Nephew SNATS (NYSE:SNN – Get Free Report) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Thursday, Zacks reports.

A number of other analysts also recently commented on SNN. Berenberg Bank set a $33.88 target price on Smith & Nephew SNATS in a research note on Friday, September 11th. Bank of America lowered Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a report on Tuesday, September 8th. Morgan Stanley cut Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, September 2nd. BTIG Research assumed coverage on Smith & Nephew SNATS in a report on Monday, August 31st. They issued a “neutral” rating for the company. Finally, Weiss Ratings lowered Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $31.91.

View Our Latest Report on Smith & Nephew SNATS

Smith & Nephew SNATS Stock Down 2.7%

NYSE:SNN traded down $0.85 during mid-day trading on Thursday, hitting $31.16. The company’s stock had a trading volume of 1,863,749 shares, compared to its average volume of 1,212,994. The business’s fifty day moving average is $28.50 and its two-hundred day moving average is $31.05. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. Smith & Nephew SNATS has a 1 year low of $26.12 and a 1 year high of $37.09.

Hedge Funds Weigh In On Smith & Nephew SNATS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its position in shares of Smith & Nephew SNATS by 20.0% in the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 387 shares during the period. Clearstead Trust LLC acquired a new position in shares of Smith & Nephew SNATS during the 2nd quarter worth about $25,000. Versant Capital Management Inc raised its position in shares of Smith & Nephew SNATS by 7.9% during the 3rd quarter. Versant Capital Management Inc now owns 8,852 shares of the medical equipment provider’s stock worth $239,000 after purchasing an additional 647 shares during the last quarter. Addison Advisors LLC purchased a new position in Smith & Nephew SNATS in the 2nd quarter valued at about $43,000. Finally, Allworth Financial LP purchased a new position in Smith & Nephew SNATS in the 2nd quarter valued at about $48,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Company Profile

(Get Free Report)

Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients’ mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.

The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.